Data from FDA - Curated by EPG Health - Last updated 31 August 2017
Indication(s)
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
Allergic Rhinitis
Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.
+ 4 more
Atopic Dermatitis
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Biosimilars in Oncology Knowledge Centre
What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.
CDK 4/6 inhibitors in metastatic breast cancer
The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.
Cardiovascular Metabolism Knowledge Centre
The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.
Chronic Lymphocytic Leukaemia (CLL)
Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more
+ 1 more
Related Content
Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure (LeoDOR)
Repetitive levosimendan infusions for patients with advanced chronic heart failure (LeoDOR) A randomised, double-blind, placebo-controlled multicentre study with parallel group design.
Added 4 days ago
Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX
The purpose of the study is to evaluate the efficacy, safety and tolerability of intravenous infusion of Levosimendan for 24hrs in patients with ADHF who will be hospitalized with ADHF and continue to have symptom of dyspnea at rest...
Added 4 days ago
Acetazolamide in Patients With Acute Heart Failure (ACETA)
The aim of this study was to evaluate the effectiveness and safety of the use of acetazolamide versus placebo in volume control in patients with decompensated HF.
Added 4 days ago
Levosimendan Versus Dobutamine for Renal Function in Heart Failure (ELDOR)
Although inotropes have a favorable effect on central hemodynamics in patients with heart failure, their effect on renal hemodynamics is incompletely defined.
Added 3 months ago
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI).
Added 5 months ago
Use of levosimendan in acute heart failure.
As a calcium sensitizer and inodilator that augments cardiac contractility without increasing myocardial oxygen demand or exacerbating ischaemia, levosimendan may be well configured to deliver inotropic support in cases of acute heart failure (AHF).
Added 4 days ago
Repetitive levosimendan treatment in the management of advanced heart failure.
Inotropes may be an appropriate treatment for patients with advanced heart failure (AdHF) who remain highly symptomatic despite optimized standard therapies.
Added 4 days ago
Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment.
Background: Bone impairment appears to be a novel complication of nephropathic cystinosis despite cysteamine therapy. Its exact underlying pathophysiology is nevertheless unclear.
Added 5 days ago
Skeletal Consequences of Nephropathic Cystinosis.
Nephropathic cystinosis is a rare lysosomal storage disorder. Patients present in the first year of life with renal Fanconi syndrome that evolves to progressive chronic kidney disease (CKD).
Added 5 days ago
Ocular changes in nephropathic cystinosis: The course of the gold-dust.
In the cornea, crystalline, gold-dust deposition of cystine leads to visual impairment, recurrent erosions, photophobia, epiphora and blepharospasmus.
Added 5 days ago
Clinical Practice Guidelines for the Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU (Devlin et al., 2018)
To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU.
Added 28 days ago
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
Added 4 months ago
Recurrent pregnancy loss
The overall aim of this guideline is to supply healthcare providers with the best available evidence for investigation and treatment of women with recurrent pregnancy loss.
Added 6 months ago
Recommendations for the Surgical Treatment of Endometriosis. Part 1: Ovarian Endometrioma
This document provides recommendations covering technical aspects of different methods of surgery for endometriomas in women of reproductive age.
Added 6 months ago
International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018
Objective: To develop and translate rigorous, comprehensive evidence-based diagnosis, assessment and treatment guidelines, to improve the lives of women with polycystic ovary syndrome (PCOS) worldwide.
Added 6 months ago
More information
Category | Value |
---|---|
Agency product number | 8P5F881OCY |
Orphan designation | No |
Product NDC | 51079-621 |
Date Last Revised | 27-09-2012 |
Type | HUMAN PRESCRIPTION DRUG |
RXCUI | 1545801 |
Marketing authorisation holder | Mylan Institutional Inc. |